Company: MYGN
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0000899923-25-000048
Chunk: 19

Company: MYRIAD GENETICS INC
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
 Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— (8.7)— — (8.7)Stock-based compensation expense— 12.0 — — 12.0 Net loss— — — (26.0)(26.0)Other comprehensive loss, net of tax— — (0.5)— (0.5)BALANCES AT MARCH 31, 2024$0.9 $1,418.8 $(4.2)$(655.5)$760.0 BALANCES AT DECEMBER 31, 2024$0.9 $1,457.8 $(0.8)$(756.8)$701.1 Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— (5.8)— — (5.8)Stock-based compensation expense— 9.5 — — 9.5 Net loss— — — (0.1)(0.1)Other comprehensive income, net of tax— — 0.2 — 0.2 BALANCES AT MARCH 31, 2025$0.9 $1,461.5 $(0.6)$(756.9)$704.9 

See accompanying notes to Condensed Consolidated Financial Statements.

7

Table of Contents

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (unaudited)

(in millions)Three months endedMarch 31,20252024CASH FLOWS FROM OPERATING ACTIVITIES:Net loss$(0.1)$(26.0)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization14.4 15.7 Non-cash lease expense2.8 2.3 Stock-based compensation expense9.5 12.0 Unrecognized tax benefits(31.3)0.6 Gain on termination of lease— (3.1)Gain on acquisition— (2.2)Other non-cash adjustments0.5 2.7 Changes in assets and liabilities:Prepaid expenses and other current assets(2.2)(5.2)Trade accounts receivable0.8 (3